Olema Pharmaceuticals Newsroom

Olema Pharmaceuticals Analyst Ratings

BenzingaJun 4 07:03 ET

Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination

TipRanksMay 16 06:11 ET

Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies

TipRanksMay 15 15:50 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaMay 15 14:00 ET

Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals

TipRanksMay 15 11:50 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaMay 9 15:32 ET

Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position

TipRanksMay 9 07:16 ET

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), 2seventy Bio (TSVT) and Marinus (MRNS)

TipRanksMay 9 07:10 ET

Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration

TipRanksMay 8 18:50 ET

Promising Future for Olema Pharmaceuticals With Palazestrant in Breast Cancer Treatment: A Buy Rating

TipRanksMay 2 06:31 ET

Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge

TipRanksApr 12 12:05 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaApr 2 07:11 ET

Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment

TipRanksMar 12 09:51 ET

Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity

TipRanksMar 12 08:10 ET

Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TipRanksMar 12 08:10 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaMar 12 06:41 ET

Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals' Palazestrant

TipRanksMar 11 20:30 ET

Buy Rating for Olema Pharmaceuticals' Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer Treatment

TipRanksMar 6 14:10 ET

Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)

TipRanksFeb 22 07:54 ET

Olema Pharmaceuticals Analyst Ratings

BenzingaJan 30 07:30 ET